Seeking Alpha

The FDA extends its review of Biogen Idec's (BIIB -2.8%) multiple-sclerosis pill BG-12 by three...

The FDA extends its review of Biogen Idec's (BIIB -2.8%) multiple-sclerosis pill BG-12 by three months, although the agency hasn't requested additional studies. Last week, Biogen said that new data provided more evidence of the the drug's effectiveness in patients with relapsing-remitting MS.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs